HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Vaginal Neoplasms (Cancer, Vaginal)

Subscribe to New Research on Vaginal Neoplasms

Tumors or cancer of the VAGINA.

Also Known As:

Cancer, Vaginal; Vaginal Cancer; Cancer of the Vagina; Neoplasms, Vaginal; Vagina Cancer; Vagina Neoplasms; Cancer, Vagina; Cancers, Vagina; Cancers, Vaginal; Neoplasm, Vagina; Neoplasm, Vaginal; Neoplasms, Vagina; Vagina Cancers; Vagina Neoplasm; Vaginal Cancers; Vaginal Neoplasm; Cancer of Vagina

Networked: 209 relevant articles (7 outcomes, 13 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Anus Neoplasms (Anal Cancer)
3.	Endometrial Neoplasms (Endometrial Cancer)
4.	Ovarian Neoplasms (Ovarian Cancer)
5.	Uterine Cervical Neoplasms (Cancer of the Cervix)

Experts

1.	Beriwal, Sushil: 9 articles (08/2015 - 10/2006)
2.	Kim, Hayeon: 5 articles (01/2015 - 10/2006)
3.	Edwards, Robert P: 4 articles (01/2015 - 10/2006)
4.	Kelley, Joseph L: 4 articles (01/2015 - 01/2008)
5.	Sukumvanich, Paniti: 4 articles (01/2015 - 01/2008)
6.	Tanaka, Eiichi: 3 articles (03/2015 - 08/2005)
7.	Rajagopalan, Malolan S: 3 articles (01/2015 - 05/2013)
8.	Baranov, S B: 3 articles (01/2010 - 01/2003)
9.	Kanaev, S V: 3 articles (01/2010 - 01/2003)
10.	Jhingran, Anuja: 2 articles (05/2015 - 05/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Vaginal Neoplasms:

1.	Cisplatin (Platino)FDA LinkGeneric 01/01/1986 - "Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group Study." 07/01/2013 - "The addition of 3-AP to cisplatin radiochemotherapy was tolerable and produced high rates of clinical and metabolic responses in women with cervical and vaginal cancers. " 11/01/2007 - "To evaluate the feasibility of concurrent weekly Cis-platinum chemoradiation (CRT) in the curative treatment of primary vaginal cancer. " 11/01/2007 - "Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum." 01/01/1986 - "Twenty-six patients with advanced or recurrent cancer of the vagina no longer amenable to control with surgery and/or radiotherapy were entered into a phase II study of cisplatin 50 mg/m2 intravenously every 3 weeks. "
2.	VaccinesIBA 09/22/2015 - "Both Gardasil® and Cervarix® vaccines when administered by a three-dose schedule have been demonstrated to be effective against cervical, vulva, and vaginal cancer precursors from vaccine genotypes in phase III clinical trials, and post-marketing studies; Gardasil® vaccine also offers additional protection against anal cancer precursors. "
3.	irinotecan (Camptosar)FDA LinkGeneric 01/01/1999 - "This is the first report on the good efficacy of chemotherapy with irinotecan and cisplatin for advanced vaginal cancer." 01/01/1999 - "Stage II vaginal cancer responding to chemotherapy with irinotecan and cisplatin: a case report." 01/01/1999 - "We report a patient with stage II primary vaginal cancer whose tumor disappeared on magnetic resonance imaging after a single course of neoajuvant chemotherapy using irinotecan and cisplatin. "
4.	Diethylstilbestrol (Stilbestrol)FDA Link 12/01/2005 - "We analyzed a 20 year-old patient case exposed in utero to diethylstilbestrol, as probably predisposed factor in vaginal cancer. " 12/01/2005 - "[Vagina cancer in a young woman exposed to diethylstilbestrol: case report and literature review]." 07/01/1989 - "Data from two case-control studies that showed an association between in utero diethylstilbestrol (DES) exposure and clear cell vaginal cancer are evaluated. " 01/01/1988 - "Cervical and vaginal cancer detection at a regional diethylstilbestrol (DES) screening clinic." 05/01/1986 - "We illustrate these ideas with the data that first showed the relationship between in utero exposure to diethylstilbestrol and cancer of the vagina in young girls."
5.	Estrogens (Estrogen)FDA Link 01/01/1985 - "The evidence for excess estrogen levels as the underlying mechanism for increased risk of uterine and vulvo-vaginal cancer is reviewed. " 03/01/1979 - "This patient is unique in that development of the vaginal neoplasm occurred in the absence of estrogen influence." 05/01/1972 - "Estrogen, vaginal cancer, and vaginal development." 11/17/2009 - "In mouse models for HPV-associated cancers, estrogen is required for the development of cervical and vaginal cancers. " 10/01/2004 - "Utilizing estrogen compounds has no bearing on risks of later developing squamous cell carcinoma of the cervix, or tubal, vulvar or vaginal cancer. "
6.	DNA (Deoxyribonucleic Acid)IBA 09/01/1989 - "Corrected 5-year survival rate in invasive vaginal cancer was 44%, with no significant relation to DNA ploidy or SPF. " 07/01/2013 - "After complete hysterectomy, the HPV DNA level in the vaginal tissue was obviously increased, and vaginal cancer was diagnosed 6 months later. " 05/01/1988 - "DNA analysis cervical and vaginal cancer cells during radiotherapy by rapid high-resolution cytometry." 08/19/2008 - "In women, HPV DNA is prevalent in 36-40% vulvar cancer cases and close to 90% of vaginal cancers. " 05/01/1988 - "The DNA content of the nuclei of cancer cells of 12 cases of cervical cancer and 2 cases of vaginal cancer, treated with radiotherapy, were studied in 50 specimens. "
7.	RadiumIBA 01/01/1984 - "[Results of treatment of primary vaginal cancer depending on the radiation dose delivered from radium applicators]." 02/01/1955 - "Treatment of primary cancer of the vagina with radium." 05/01/1952 - "[Blood protein changes in uterine and vaginal neoplasms treated with radium and roentgen rays]." 02/01/2002 - "Treatment results obtained with high-dose-rate brachytherapy are at least similar to traditional radium therapy for primary vaginal cancer." 05/31/1955 - "[A case of vaginal tuberculosis appearing after radium therapy of vaginal cancer]."
8.	squamous cell carcinoma-related antigenIBA 11/01/2015 - "Recurrence of vaginal cancer was suspected because of the elevation of serum squamous cell carcinoma antigen level. " 06/01/1989 - "Serum squamous cell carcinoma antigen levels in patients with invasive squamous vulvar and vaginal cancer: a preliminary report." 08/01/1989 - "With a cutoff value of 2.23 ng/ml (2 SD above the mean of the control group), the rate of SCC antigen elevation was 54% in cervical cancer (78), 14% in vulvar or vaginal cancer (7), 22% in ovarian cancer (18), and 10% in endometrial cancer (10). " 07/01/1997 - "At a cut-off value of 4.8 ng/ml (100% specificity), the rate of SCC antigen elevation was 100% in vulvar and vaginal cancer (n = 5), 90% in ovarian cancer (n = 10), 60.0% in endometrial cancer (n = 10) and 57.2% in cervical cancer (n = 7). "
9.	tranilast (N 5')IBA 12/01/1988 - "Thirty-five patients with advanced gynecologic malignancies (cervical cancer, N = 26; endometrial cancer, N = 5; ovarian cancer, N = 2; vaginal cancer, N = 2) underwent cystoscopy and subsequent cystosonography. " 03/01/2008 - "Malignancies included breast cancer (n = 39, 43%), ovarian cancer (n = 32, 35%), cervical cancer (n = 12, 13%), endometrial cancer (n = 5, 6%), fallopian tube cancer (n = 2, 2%), and vaginal cancer (n = 1, 1%). " 01/27/2009 - "Safety was assessed weekly, and dose-limiting toxicity (DLT) was evaluated in cycle 1. A total of 16 patients (median age 54.5 years, range 33-69) were entered; 11 had prior taxane therapy for breast (n=5), ovarian (n=3), and vaginal cancer (n=1) or angiosarcoma (n=2). " 07/01/1997 - "At a cut-off value of 4.8 ng/ml (100% specificity), the rate of SCC antigen elevation was 100% in vulvar and vaginal cancer (n = 5), 90% in ovarian cancer (n = 10), 60.0% in endometrial cancer (n = 10) and 57.2% in cervical cancer (n = 7). "
10.	Benzydamine (Tantum)IBA 01/01/2010 - "[Ten-year experience with use of Tantum Rosa drug for prevention and therapy of radiation-related rectitis and vaginitis in uterine and vaginal cancer]." 01/01/2003 - "[Experience with tantum rosa treatment for the prevention and management of radiation-induced proctitis and vaginitis in uterine and vaginal cancer]." 01/01/2007 - "[Clinical experience with tantum rosa (benzydamine hydrochloride) in prophylaxis and treatment of vaginitis and proctitis, following radiotherapy of patients with cancer of the vagina and uterus]."

Therapies and Procedures

1.	Brachytherapy 02/01/2002 - "To evaluate the efficacy of radiation therapy on primary vaginal cancer with high-dose-rate brachytherapy alone or in combination with external radiation. " 01/01/2008 - "The purpose of this study was to evaluate the efficacy of HDR brachytherapy for primary or recurrent vaginal cancer. " 10/01/1984 - "In 1976, we began to test californium-252 neutron brachytherapy (NT) for its efficacy for control of primary and recurrent advanced uterine, cervix, and vaginal cancers. " 10/01/2006 - "The study aimed to assess the outcome of locally advanced cervical and vaginal cancer treated with high-dose-rate interstitial brachytherapy (HDRB). " 08/01/2015 - "The aim of this manuscript is to outline the incorporation of modern brachytherapy into the treatment of patients with vaginal cancer including patient selection along with the role of brachytherapy in conjunction with other treatment modalities, various brachytherapy techniques, treatment planning, dose fractionation schedules, and normal tissue tolerance. "
2.	Radiotherapy 01/01/2015 - "Though early stage vaginal cancers have better outcome treated with surgery or radiotherapy or surgery followed by radiotherapy, radiotherapy alone is preferred mode of treatment in vaginal cancers." 12/01/2015 - "The aim of this study was to review treatment and outcomes of patients with primary vaginal cancer treated with definitive radiotherapy. " 03/01/2015 - "The purpose of this study was to determine the outcomes and optimal practice patterns of definitive radiotherapy for primary vaginal cancer. " 03/01/2012 - "This study was performed to evaluate treatment outcomes and define prognostic factors for primary vaginal cancer treated with definitive radiotherapy. " 12/01/2015 - "Radiotherapy provides excellent results as definitive treatment for primary vaginal cancer, although the risk of severe complications is high. "
3.	Drug Therapy (Chemotherapy) 11/01/2008 - "The objective of this study was to analyse the feasibility and results obtained by neoadjuvant chemotherapy followed by surgery in patients affected by invasive vaginal cancer with paravaginal tissue involvement not reaching the pelvic side wall. " 01/01/2006 - "The number of studies concerning endometrial, vulvar and vaginal cancers are few in the area of neoadjuvant chemotherapy." 05/01/2015 - "We report 2 cases of ovarian torsion after laparoscopic ovarian transposition in 2 young women scheduled for chemotherapy and radiation therapy for treatment of cervical or vaginal cancer. " 01/01/2013 - "Concurrent chemotherapy should be considered for vaginal cancer patients." 01/01/2013 - "Seventy-one patients with primary vaginal cancer treated with definitive RT with or without concurrent chemotherapy at a single institution were identified and their records reviewed. "
4.	Hysterectomy 03/27/1996 - "We considered (1) organizations' recommendations about screening, (2) references from major textbooks of gynecology, and (3) MEDLINE searches of English-language studies published from 1966 through 1995 using the search strategy (hysterectomy and vaginal smears) or (vaginal smears and vaginal neoplasms). " 01/01/2016 - "Women diagnosed with VaIN2 and with previous hysterectomy for human papillomavirus-related cervical diseases should always be carefully evaluated and possibly excised, given the higher risk of histopathological upgrading of lesions and thus the potential risk of occult vaginal cancer. " 01/01/2013 - "Four patients underwent LUV after hysterectomy for high risk VAIN and early vaginal cancer. " 12/01/2006 - "There was only one report of vaginal cancer subsequent to hysterectomy for CIN and insufficient data to allow for reliable meta-analysis. " 07/01/2003 - "Cost-effectiveness of pap smear screening for vaginal cancer after total hysterectomy for benign disease."
5.	Pelvic Exenteration 11/01/2014 - "The aim of this study was to assess the prognostic factors after curative pelvic exenterations performed for recurrent uterine cervical or vaginal cancers in the era of concomitant chemoradiotherapy. " 11/01/2014 - "Prognostic factors for curative pelvic exenterations in patients with recurrent uterine cervical or vaginal cancer." 05/01/2013 - "Does histologic type correlate to outcome after pelvic exenteration for cervical and vaginal cancer?" 02/01/2013 - "[Total pelvic exenteration in vaginal cancer--case report]." 07/01/2007 - "To determine the accuracy of (18)FDG PET in identifying sites of metastatic disease prior to pelvic exenteration or radical resection in patients (pts) with recurrent cervical or vaginal cancers. "